UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  

FORM 8-K  
CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934  

Date of Report (Date of earliest event reported) August 20, 2021 (August 19, 2021)  

Merck & Co., Inc.  
(Exact name of registrant as specified in its charter)  

New Jersey  1-6571  22-1918501  
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)  

2000 Galloping Hill Road, Kenilworth, NJ  07033  
(Address of principal executive offices) (Zip Code)  

Registrant’s telephone number, including area code (908) 740-4000  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:  
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.  
Emerging growth company ☐  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐  

Securities registered pursuant to Section 12(b) of the Act:  

<table>
<thead>
<tr>
<th>Title of Each Class</th>
<th>Trading Symbol(s)</th>
<th>Name of Each Exchange on which Registered</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock ($0.50 par value)</td>
<td>MRK</td>
<td>New York Stock Exchange</td>
</tr>
<tr>
<td>1.125% Notes due 2021</td>
<td>MRK/21</td>
<td>New York Stock Exchange</td>
</tr>
<tr>
<td>0.500% Notes due 2024</td>
<td>MRK24</td>
<td>New York Stock Exchange</td>
</tr>
<tr>
<td>1.875% Notes due 2026</td>
<td>MRK/26</td>
<td>New York Stock Exchange</td>
</tr>
<tr>
<td>2.500% Notes due 2034</td>
<td>MRK/34</td>
<td>New York Stock Exchange</td>
</tr>
<tr>
<td>1.375% Notes due 2036</td>
<td>MRK36A</td>
<td>New York Stock Exchange</td>
</tr>
</tbody>
</table>
(b) Incorporated by reference is a press release issued by Merck & Co., Inc. (the “Company”) on August 20, 2021, attached as Exhibit 99.1, announcing the resignation of Leslie A. Brun from the Company’s Board of Directors effective August 19, 2021.

Item 9.01 – Financial Statements and Exhibits.

(d) Exhibits:

<table>
<thead>
<tr>
<th>Exhibit Number</th>
<th>Description</th>
</tr>
</thead>
</table>
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Merck & Co., Inc.

Date: August 20, 2021

By:  /s/ Kelly E. W. Grez

Name:  Kelly E. W. Grez

Title:  Deputy Corporate Secretary
<table>
<thead>
<tr>
<th>Exhibit No.</th>
<th>Description of Exhibit</th>
</tr>
</thead>
</table>
FOR IMMEDIATE RELEASE

Media Contacts: Patrick Ryan
(973) 275-7075

Melissa Moody
(215) 407-3536

Investor Contacts: Peter Dannenbaum
(908) 740-1037

Raychel Kruper
(908) 740-2107

Leslie A. Brun Resigns from Merck Board of Directors

KENILWORTH, N.J., Aug. 20, 2021 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Leslie A. Brun, its independent lead director, has resigned from its Board of Directors, effective August 19, 2021. Mr. Brun is stepping down due to his decision to become chairman and chief executive officer of Ariel Alternatives, LLC, a subsidiary of Ariel Investments, LLC, a private equity initiative being created to help scale minority-owned businesses to serve as tier 1 suppliers to Fortune 500 companies. Merck is currently evaluating making an investment with Ariel Alternatives.

“Les has been an invaluable member of Merck’s board for many years and we have benefitted greatly from his leadership, wise counsel and friendship,” said Rob Davis, chief executive officer and president, Merck. “While we will miss him, we recognize the importance of the task Les is undertaking at Ariel Alternatives, and we wish him great success.”

The company intends to name a new independent lead director in the near future.

About Merck

For 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

# # #

Page 2